期刊文献+

重症感染患者替考拉宁血药谷浓度68例次监测分析 被引量:11

Analysis of serum trough concentration of teicoplanin in 68 times of monitoring in patients with severe infection
暂未订购
导出
摘要 目的通过监测重症感染患者替考拉宁血药谷浓度变化,为重症患者合理使用替考拉宁提供参考。方法回顾性分析2015年1月至2016年12月入住我院重症监护病房(ICU)使用并监测替考拉宁血清谷浓度的重症患者41例,分析替考拉宁血药谷浓度的分布情况、影响因素及临床疗效。结果 41例患者共计68例次替考拉宁谷浓度检测结果,其中仅30.89%(21/68)达到目标范围(10~60 mg/L),而未达标(<10 mg/L)达69.11%(47/68);多重线性回归分析显示,除肌酐清除率外(P=0.039),年龄、性别、体重、APACHE2评分、白蛋白及血肌酐对替考拉宁血药谷浓度的影响均无统计学意义(P>0.05);替考拉宁谷浓度达标者与未达标者死亡率比较差异无统计学意义(χ~2=1.066,P=0.302)。结论替考拉宁在重症患者中血药谷浓度达标率低,个体差异大,肌酐清除率对替考拉宁血药谷浓度影响较大,建议通过血药浓度监测的方法制定个体化给药方案。 Objective To provide a reference for the rational use of teicoplanin in critically ill patients by monitoring the changes in serum trough concentration of teicoplanin. Methods Forty-one critically ill patients who were admitted to intensive care unit( ICU) in our hospital from January 2015 to December 2016 were chosen,and then the data was collected and analyzed retrospectively and the serum trough concentration was monitored. The distribution,influencing factors and clinical efficacy of serum trough concentration of teicoplanin were analyzed retrospectively. Results There were 68 results of serumn trough concentration,in which 21( 21/68,30. 89%) reached the target range( 10 - 60 mg/L)and 47( 47/68,69. 11%) did not reach the target range(〈10 mg/L). Only creatinine clearance rate was found to be correlated with serum trough concentration by multiple linear regression analysis( P = 0. 039),while age,gender,body weight,APACHE2,albumin and serum creatinine had no significant influence on the serum trough concentration( P〈0. 05). There was no significant difference in the mortality between the patients whose serum trough concentration reached the standard and those whose concentration did not( χ^2= 1. 066,P = 0. 302). Conclusion The rate of serum trough concentration of teicoplanin reaching standard in patients with critical illness is low with great individual variability. The creatinine clearance rate has great influence on the serum concentration of teicoplanin,and the individualized schedule of drug treatment should be made.
作者 梁培 郭晓芳 LIANG Pei;GUO Xiao-fang(Department of Pharmacy;Department of ICU, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China)
出处 《实用药物与临床》 CAS 2018年第5期553-556,共4页 Practical Pharmacy and Clinical Remedies
关键词 重症患者 替考拉宁 血药谷浓度 Critical patient Teicoplanin Serum trough concentration
  • 相关文献

参考文献4

二级参考文献38

  • 1艾又生,徐楚鸿,陈志祥,陈华庭.高效液相色谱法测定替考拉宁的血药浓度[J].中国医院药学杂志,2005,25(3):254-256. 被引量:19
  • 2Wood MJ. Comparative safety of teicoplanin and vancomycin [J]. J Chemother,2000,12(5) :21-25.
  • 3B Sato M,Chida K,Suda T,et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monito- ring,and outcome in terms of optimal trough level[J]. J Infect Chemother,2006,12(4) : 185-189.
  • 4Rose WE, Kaatz GW, Sakoulas G, et al. Teicoplanin pharmaco- dynamics in reference to the accessory gene regulator (agr) in Staphylococcus aureus using an in vitro pharmaeodynamic model[J]. J Antimicrob Chemother,2008,61 (5) : 1099-1102.
  • 5Nobuo M, Keiko O, Tsuyoshi S, et al. Quantitative determina- tion of individual teicoplanin components in human plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection[J]. J Chrom B, 2007, 847 (2) : 78- 81.
  • 6Yano R, Nakamura T, Tsukamoto H,et al. Variability in teico- planin protein binding and its prediction using serum albumin eoncentrations[J].Ther Drug Monit, 2007,29 (4) : 399-403.
  • 7Federico P, Loris B, Pierluigi V, et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose[J].J Antimicro- bial Chem,2003,51 (4) :971-975.
  • 8Neumar RW, Nolan JP, Adrie C, et al. Post-cardiac arrest syn-drome: epidemiology, pathophysiology, treatment, and prognos-tication. A consensus statement from the International LiaisonCommittee on Resuscitation (American Heart Association, Aus-tralian and New Zealand Council on Resuscitation, EuropeanResuscitation Council, Heart and Stroke Foundation of Cana-da, InterAmerican Heart Foundation, Resuscitation Council ofAsia, and the Resuscitation Council of Southern Africa) ; theAmerican Heart Associatior) Emergency Cardiovascular CareCommittee; the Council on Cardiovascular Surgery and Anesthe-sia ;the Council on Cardiopulmonary, Perioperative, and Criti-cal Care; the Council on Clinical Cardiology, and the StrokeCounciJ[j]. Circulation, 2008,118(23):2452-2483.
  • 9Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiol-ogy ,risk stratification, and outcomes [J]. Kidney Int, 2012,81(9):819-825.
  • 10Bresolin N, Bianchini AP, Haas CA. Pediatric acute kidney in-jury assessed by RIFLE as a prognostic factor in the intensivecare unit[j j. Pediatr Nephrol, 2013,28(3) :485-492.

共引文献35

同被引文献56

引证文献11

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部